BLACK SEA HORIZON – Bi-regional STI Dialogue

FundingCalls for funding opportunities

NMBP-16-2017: Mobilising the European nano-biomedical ecosystem

Developing innovative nanomedical products for a more personalized, predictive and efficient medicine requires further integration of nanotechnologies aiming at applications in human health notably with further Key Enabling Technologies. It also needs a functioning ecosystem of actors, in which the research, translation, regulation, standardization and take-up of innovative nanomedicines by the different European healthcare systems is stimulated. End-of-life/disposal and recyclability issues should also be addressed as appropriate.

NMBP-16-2017: Mobilising the European nano-biomedical ecosystem
  • Deadline: 19.01.2017
  • Call Date: 10.11.2016

Website: Link

Scope:

Supporting the development of an ecosystem for nanomedicine in Europe, including activities such as coordinating national platforms and regional clusters; developing common training material and services; international cooperation related to community building, road-mapping, regulation, manufacturing, reimbursement and pricing, standardization and recyclability; and reaching out to attract the interest of citizens, young talents and young entrepreneurs. Collaborations with relevant technology platforms or similar initiatives in Europe or worldwide will allow deeper and more effective cross-KETs activities for innovative integrated solution and well as a consolidated international strategy for the sector.

Attention should be paid to achieve a cross-regional, cross-sectoral and cross-technological approach, based on the analysis of relevant roadmaps, strategic research agendas or smart specialisation strategies which have listed nanomedicine or personalised Medicine as one of their priorities. These different approaches might for instance be united into one “meta” roadmap.

The Commission considers that proposals requesting a contribution from the EU between EUR 1 and 2 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected Impact:

  • Increased take-up of innovative Nanomedicine solutions by industry and SMEs, end-users, regulatory and public authorities, healthcare insurances, doctors and patients, research organisations and academia;
  • Improvement of cross-KETs activities to provide better integrated healthcare solutions;
  • Increased international networking with new potential market opportunities;
  • Improvement of the competitiveness of the European healthcare sector.

Please read carefully all provisions below before the preparation of your application.

  1. LIST OF COUNTRIES and APPLICABLE RULES FOR FUNDING
    described in part A of the General Annexes of the General Work Programme.

    Note also that a number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon 2020 projects (follow the links to Australia, Brazil, Canada, ChinaHong Kong &Macau, India, Japan, Republic of Korea, Mexico, Russia, Taiwan).
     
  2. ELIGIBILITY and ADMISSIBILITY CONDITIONS
    described in part B and C of the General Annexes of the General Work Programme.

    Proposal page limits and layout: Please refer to Part B of the standard proposal template.
     
  3. EVALUATION

    3.1  Evaluation criteria and procedure, scoring and threshold:

    The criteria, scoring and threshold are described in General Annex H of the work programme.

    The procedure for setting a priority order for proposals with the same score is given in General Annex H of the work programme. The following exceptions apply:

    Under 3 (a)
    Proposals are first ranked in separate lists according to the topics against which they were submitted (‘topic ranked lists’). When comparing ex aequo proposals from different topics, proposals having a higher position in their respective 'topic ranked list' will be considered to have a higher priority in the overall ranked list.

    Under 3 (b)
    For all topics and types of action, the prioritisation will be done first on the basis of the score for Impact, and then on that for Excellence.

    3.2 Submission and evaluation process: Guide to the submission and evaluation process 

  4. INDICATIVE TIMETABLE for EVALUATION and GRANT AGREEMENT

    Information on the outcome of single-stage evaluation: maximum 5 months from the deadline for submission.
    Signature of grant agreements: maximum 8 months from the deadline for submission.
     
  5. PROVISIONS, PROPOSAL TEMPLATES and EVALUATION FORMS
    for the type of action under this topic


    Coordination and Support Action:

    Specific provisions and funding rates
    Standard proposal template
    Standard evaluation form
    H2020 General MGA -Multi-Beneficiary
    Annotated Grant Agreement
     
  6. ADDITIONAL PROVISIONS

    Horizon 2020 budget flexibility

    Classified information

    Technology readiness levels (TRL) – where a topic description refers to TRL, these definitions apply.

    Financial support to Third Parties – where a topic description foresees financial support to Third Parties, these provisions apply.
     
  7. OPEN ACCESS

    Open access must be granted to all scientific publications resulting from Horizon 2020 actions.

    Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.

    Open access to research data

    The Open Research Data Pilot has been extended to cover all Horizon 2020 topics for which the submission is opened on 26 July 2016 or later. Projects funded under this topic will therefore by default provide open access to the research data they generate, except if they decide to opt-out under the conditions described in annex L of the Work Programme. Projects can opt-out at any stage, that is both before and after the grant signature.

    Note that the evaluation phase proposals will not be evaluated more favourably because they plan to open or share their data, and will not be penalised for opting out.

    Open research data sharing applies to the data needed to validate the results presented in scientific publications. Additionally, projects can choose to make other data available open access and need to describe their approach in a Data Management Plan.

    - Projects need to create a Data Management Plan (DMP), except if they opt-out of making their research data open access. A first version of the DMP must be provided as an early deliverable within six months of the project and should be updated during the project as appropriate. The Commission already provides guidance documents, including a template for DMPs.

    - Eligibility of costs: costs related to data management and data sharing are eligible for reimbursement during the project duration.

    The legal requirements for projects participating in this pilot are in the article 29.3 of the Model Grant Agreement.

ADDITIONAL DOCUMENTS

Program: Horizon 2020 | Scientific field: Materials science and engineering | Related Topics: Research and innovation community | Geographical focus: Black Sea Region, Countries associated to Horizon 2020

Related Content

Black Sea Horizon Grant Scheme  to facilitate the participation of Black Sea countries in Brokerage Events – 2nd CALL -  APPLY NOW!
  • Call
  • Posted on: 10.11.2016

Black Sea Horizon Grant Scheme to facilitate the participation of Black Sea countries in Brokerage Events – 2nd CALL - APPLY NOW!

This grant scheme financially supports the participation of local researchers from Black Sea countries in brokerage events related to Horizon2020 in the...

read more